Amplification of PRR11 was predominant in breast cancer, Pleural Mesothelioma, cholangiocarcinoma, and pheochromocytoma, while deep deletion was prevalent in prostate cancer. This evidence concerns the gene PRR11 and hereditary pheochromocytoma-paraganglioma.